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The purpose of this research study was to develop 5-fluorouracil compression coated tablets by using 
biodegradable polysaccharide polymer locust bean gum (LBG) and hydroxyl propyl methyl cellulose 
(HPMC) as coating materials. The fast disintegrating core tablets containing 50 mg of 5-fluorouracil were 
compression coated with LBG and HPMC in different ratios (8:1, 7:2 and 6:3) with a coat weight of 300, 
400 and 500 mg. In vitro dissolution data indicated that the formulation (CLH63) with a coat weight of 500 
mg containing LBG and HPMC in the ratio 6:3 gave the best release profile (0% in first 5 hour and 96.18% 
in 24 hours). DSC and FTIR results indicated no possibility of interaction between drug and polymers or 
other excipients. In vivo human X-ray studies revealed that formulation CLH63 was able to resist breakdown 
in the stomach and small intestine. The disintegration of the tablet occurred in the colon between 8 to 16 
hours of post dose. By the present study, it can be concluded that the LBG and HPMC based compression 
coated tablets of 5-fluorouracil will be useful strategy for colonic delivery of 5-fluorouracil without being 
released in upper gastrointestinal region for the safe and effective management of colon cancer.
Uniterms: Compression coated tablet. Locust bean gum. Colon targeting. 5-fluorouracil. Colon cancer 
and X-ray.
O propósito desta pesquisa foi desenvolver comprimidos revestidos de fluoruracila utilizando 
polissacarídio biodegradável polymer locust bean gum (LBG) e hidroxipropilmetil celulose (HPMC) 
como materiais de revestimento. Os comprimidos de desintegração rápida contendo 50 mg de fluoruracila 
foram revestidos por compressão com LBG e HPMC em diferentes proporções (8:1, 7:2 e 6:3), com 
peso de cobertura de 300, 400 e 500 mg. Os dados da dissolução in vitro indicaram que a formulação 
(CLH63) com peso de cobertura de 500 mg contendo LBG e HPMC na proporção de 6:3 forneceu o 
melhor perfil de liberação (0% nas primeiras 5 horas e 96,18% em 24 horas). Os resultados de DSC e de 
FTIR não indicaram interação entre o fármaco e os polímeros ou outros excipientes. Os estudos de raios 
X in vivo revelaram que a formulação CLH63 foi capaz de resistir à quebra no estômago e no intestino 
delgado. A desintegração do comprimido ocorreu no cólon, entre 8 e 16 horas após a administração da 
dose. Pelo presente estudo, concluiu-se que os comprimidos de fluoruracila revestidos com LBG e HPMC 
por compressão se constituirão em estratégia útil na liberação de fluoruracila no cólon, para o tratamento 
seguro e efetivo do câncer de cólon, sem que o fármaco seja liberado na região gastrointestinal superior.
Unitermos: Comprimido de revestimento por compressão. Locust bean gum. Direcionamento para o 
cólon. Fluoruracila. Câncer de colon e raios X. 
INTRODUCTION
Colon-specific drug delivery systems (CDDS) 
have attracted a great deal of interest recently for safe 
and effective therapy for the local treatment of colonic 
disorders such as Crohn’s diseases, infectious diseases, 
irritable bowel syndrome, ulcerative colitis and colon 
cancer (Samia et al., 2007; Akhgari et al., 2009). Drug 
targeting to colon would also be useful when a delay in 
drug absorption is desired from therapeutic point of view, 
such as treatment of diseases that have peak symptoms 
in the early morning like nocturnal asthma, angina or 
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arthritis (Valluri et al., 2008). Further it is found to be 
a promising site for systemic absorption of peptide and 
proteins. This is because the peptide and protein drugs 
gets destroyed or inactivated in acidic environment of the 
stomach or by pancreatic enzymes in the small intestine 
(Chellan et al., 2002). Colonic drug delivery may be 
achieved by either oral or rectal administration (Mayur et 
al., 2009). Conventional oral dosage forms are ineffective 
in delivering drugs to the colon due to absorption and /or 
degradation of the active ingredient in the upper part of the 
gastrointestinal tract (GIT). Rectal dosage forms (enemas 
and suppositories) are not always much effective due to 
high variability in the distribution of drug administered by 
this route (Sinha et al., 2004). Therefore, colon-specific 
drug delivery systems, which can deliver drugs to the 
lower gastrointestinal tract without releasing them in the 
upper part of GI tract, can be expected to decrease the 
side-effects of the drug and improve the quality of life for 
the patients suffering from colon-specific diseases (Samia 
et al., 2007).
The various approaches that have been studied for 
targeting orally administered drugs to the colon include 
use of pH sensitive polymers, time dependent dosage 
forms and the use of carriers degraded by the enzymes 
produced by colonic bacteria (Ashford et al, 1993; 
Rama Prasad et al., 1998). Of these approaches, the use 
of materials that are degraded by the colonic microflora 
has been found to be the most promising because of 
their site specificity (Potts et al., 1999). Because of the 
presence of biodegradable enzymes only in the colon, 
the use of biodegradable polymers for colon specific 
drug delivery seems to be a more site-specific approach 
as compared to other approaches. These polymers shield 
the drug from the environment of stomach and small 
intestine and are able to deliver the drug to the colon. On 
reaching the colon, they undergo assimilation by micro-
organisms or degradation by enzymes or breakdown of 
the polymer backbone leading to a subsequent reduction 
in their molecular weight and thereby loss of mechanical 
strength. They are then unable to contain drug entity 
(Huang et al., 1979; Ratner et al., 1998; Park, et al., 
1993).
Complicated by physiological variation in 
gastrointestinal condition, many Colon specific drug 
delivery systems (CDDS) designs reported in literature 
have problems. The goal of CDDS is to cut off precolon 
drug release and release drug right at the afflicted site. 
Among the strategies, compression coated systems seem 
to be superior in preventing premature drug release in 
stomach and small intestine, while beginning to release 
the active agents at the proximal colon. On the other hand, 
the compression coated systems, usually in tablet form, is 
convenient to manufacture, and no special coating solvents 
or coating equipment are needed for coating process 
(Baojain et al., 2007).
Colorectal cancer is a common cancer secondary only 
to lung cancer. 5-Fluorouracil is a pyrimidine analogue and 
is the drug of choice for colon cancer (Calabresi, Chabner, 
1996). Usually it is administered parenterally because 
absorption after ingestion is unpredictable and incomplete 
(Hahn et al., 1975). Distribution of 5-fluorouracil to 
undesired sites produces severe toxic effects of the 
gastrointestinal, hematological, cardiac, neural and 
dermatological (Diasio, Harris, 1998). Targeting of 
5-fuorouracil to the colon for the treatment of colon cancer 
would not only reduces its systemic toxicity but would 
also show desired action with a reduced dose. Therefore 
in the present investigation, based on the physiological 
characteristics of the GIT, features of enzyme dependent 
systems and formulation strategies, it could be predicted 
that such functions into the single delivery systems seems 
to be desirable to achieve the site-specificity of drug 
release in the physiological environment of colon. The 
present research study was proposed to develop a novel 
biodegradable polysaccharide based compression coated 
tablet formulations for delivering 5-fuorouracil into the 
colon by using locust bean gum as a carrier in combination 
with HPMC and to characterize its colon site-specificity. 
The developed formulation consisted of two parts, i.e., 
a fast disintegrating and dissoluting 5-fuorouracil core 
tablet and outer compression coating layer which could 
protect or reduce immature drug release in the upper part 
of gastro intestinal tract and expected to release only in 
the colon after oral administration due to degradation of 
the LBG present in the coat by the caecal enzymes action 
in the colon.
MATERIAL AND METHODS
Material
5-Fluorouracil batch No. 25310FU0108131 (98.0 
to 102.0 % pure) was given by Strides Acrolabs ltd., 
Bangalore, India as a gift sample. Locust bean gum 
was obtained as a gift sample from lucid colloids Pvt. 
Ltd., Mumbai, India. Hydroxy propyl methyl cellulose 
(Colorcon Asia pvt. Ltd. Goa), crosscarmellose sodium 
and spray dried lactose (Aurobindo pharma, Hyderabad) 
was obtained as a gift sample. Starch, talc and magnesium 
stearate (S.D. fine chem. ltd.) were obtained from the local 
market. All other reagents and chemicals used were of 
analytical reagent grade.
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Methods
Preparation of 5-fluorouracil compression coated 
tablets
·	 Preparation of fast disintegrating and dissoluting 
5-fluorouracil core tablets
Fast disintegrating and dissoluting 5-fluorouracil 
core tablets (5-FLU core) were prepared by direct 
compression formula (Table I) by using spray dried 
lactose as a direct compression aid and croscarmellose 
sodium as super disintegrating agent. The 5-fluorouracil, 
crosscarmellose sodium, lactose, magnesium stearate and 
talc were accurately weighed and thoroughly mixed with 
mortar and pestle and passed through the mesh (150 µm) 
to ensure complete mixing of all the ingredients. The 
uniformity of mixing was assessed by conducting content 
uniformity test on the sample of powder mixture. Quantity 
weighing 100 mg was compressed into tablets using 6 mm 
round, flat and plain punches on a single station tableting 
machine (Cadmach, India).
·	 Preparation of 5-fluorouracil compression coated 
tablets:
The developed 5-fluorouracil core tablets were 
compression coated with a coat weight of 500 mg (core 
coat ratio 1:5), 400 mg (core coat ratio 1:4) and 300 mg 
(core coat ratio 1:3) containing different ratios of LBG and 
HPMC. Formulae of different granular coat composition 
of LBG and HPMC in the ratio 8:1, 7:2 and 6:3 with 
various excipients were listed in Table II. For compression 
coating about 45% of coat weight was first placed in the die 
cavity followed by carefully centering the core tablet and 
filled with the remainder 55% of coat weight. The coating 
material was then compressed around the core tablet by 
using single-station tableting machine with 10 mm plain 
punches.
·	 Physical evaluation tests for 5-fluorouracil core and 
compression coated tablets
Standard physical  tests  for  the developed 
5-fluorouracil core and compression-coated tablets were 
performed and average values calculated. Weight variation 
was determined by weighing 20 tablets individually, and 
the average mass and percent variation of each tablet 
was calculated. Hardness was determined by taking 5 
tablets from each batch using a Monsanto hardness tester 
(Electrolab Pvt. Ltd., India) and the average pressure 
(kgcm–2) applied to crush the tablet was determined. 
Friability was tested on ten tablets by first weighing and 
then placing them in a Roche Friabilator, which rotated for 
4 min or 100 revolutions. After dusting, the total remaining 
mass of the tablets was recorded and the percent friability 
calculated. (Lachman et al., 1987).
Estimation of drug content
The 5-fluorouracil cores as well as compression 
coated tablets were tested for their drug content to 
ensure uniformity in drug content. The 10 tablets were 
finely powdered, and quantity of the powder equivalent 
to 50 mg of 5-fluorouracil was accurately weighed and 
transferred to 100 mL volumetric flasks containing 50 mL 
of phosphate buffer pH 6.8 and allowed to stand for 6 hour 
with intermittent shaking to ensure complete solubility 
of the drug. The solution then made up to 100 mL 
with phosphate buffer pH 6.8 and mixed thoroughly. 
The solution was filtered, diluted and drug content was 
estimated by UV-spectrophotometer at the λ max 266 nm 
(Shimadzu, Japan).
In vitro dissolution studies
·	 In simulated gastric and intestinal fluid
The abi l i ty  of  LBG polysaccharide based 
5-fluorouracil compression coated tablets to protect the 
drug during the transit time in the gastro intestine region 
was assessed by mimicking mouth to colon transit. 
Drug release studies were carried out using USP XXIII 
dissolution basket method (100 rpm and 37 ± 0.5 oC) 
in 900 mL pH 1.2 buffer solution for the first 2 hour, 
as the average gastric emptying time is 2 hour, then the 
dissolution media is replaced with pH 7.4 phosphate buffer 
TABLE I - Composition of fast disintegrating and dissoluting 5-fluorouracil core tablet
S.No. Ingredients Category Quantity/Tablet (in mg)
1. 5-fluorouracil Active ingredient 50
2. Croscarmellose sodium Super disintegrant 05
3. Spray dried lactose Direct compression aid 42
4. Magnesium stearate Lubricant 02
5. Talc Glidant 01
Total composition ----- 100 mg/tablet
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for 3 hour, as the usual small intestine transit time is 3-5 
hour and dissolution was continued in phosphate buffer 
pH 6.8 up to 24 hour to stimulate the gastrointestinal 
environment as the usual colon transit time is 20-30 hour. 
Samples (5 mL) were withdrawn and replaced with fresh 
medium at fixed time intervals. The sample was suitably 
diluted and analyzed for percentage of drug release by UV 
spectrophotometer at the λ max 266 nm.
·	 In simulated rat caecal content fluid
The susceptibility of locust bean gum coat to 
the enzymatic action of colonic bacteria was assessed 
by continuing the drug release studies in presence of 
rat caecal contents because of its similarity to human 
intestinal microflora (Oluwatoyin, John, 2005). The 
caecal contents were obtained from male albino rats 
after pretreatment with 1ml of 2% w/v LBG dispersion 
in water using gavage for 7 days in order to induce the 
enzymes acting on polysaccharides. At 45 min before the 
drug release studies, rats were killed by spinal traction. 
Their abdomen were opened, the caecum isolated, caecal 
content removed, weighed and suspended in phosphate 
buffer (pH 6.8) solution which was previously bubbled 
with CO2 to give a final dilution of 4 % w/v, which had 
been reported to provide the best conditions for assessing 
the susceptibility to colonic degradation (Prasad et al., 
1998). Ethical clearance for the handling of experimental 
animals as per CPSCEA guidelines was obtained from 
the Institutional Animal Ethical Committee (IAEC) 
constituted for the purpose. The in vitro drug release 
studies simulating in colon were carried out in USP 
dissolution rate test apparatus (Apparatus 1, 100 rpm, 
37 ± 0.5 oC) with slight modifications as reported earlier by 
many researchers (Prasad et al., 1998). A beaker (capacity 
250 mL ) containing 200 ml of rat caecal content medium 
was immersed in the water maintained in 1000 mL vessel, 
which in turn, was in the water bath of the apparatus. The 
5-fluorouracil tablet formulation after completing the 
dissolution studies in pH 1.2 buffer (2 hour) and phosphate 
buffer pH 7.4 (3 hour) were placed in the basket of the 
apparatus and immersed in the phosphate buffer pH 6.8 
containing 4% w/v rat caecal conetnt contained in 250 mL 
beaker and dissolution studies continued up to 24 hour. 
As the cecum is naturally anaerobic, the experiment was 
carried out with continuous supply of carbondioxide into 
the beaker containing rat caecal medium. At the end of 
the time period 5 mL samples were withdrawn, suitably 
diluted, centrifuged to remove debris and analyzed for 
percentage of drug release by UV spectrophotometer at 
the λ max 266 nm.
In vivo human x-ray studies
X ray imaging was used to monitor the tablets 
throughout the GI system. Two healthy human volunteers 
with an age group of 34-36 years and 68-70 kg body weight 
were recruited in the in vivo studies. Volunteers were non 
alcoholic, non smoker and had not taken any drugs. The 
purpose of the study was fully explained and volunteers 
had given their written consent. After an overnight fast, 
TABLE II - Composition of granular coat formulations for compression coating on 5-fluorouracil core tablets
S.No. Ingredients Category
Quantity / Tablet (in mg)
ALH81 ALH72 ALH63 BLH81 BLH72 BLH63 CLH81 CLH72 CLH63
1. Locust Bean 
gum
Biodegradable 
polymer
240 210 180 320 280 240 400 350 300
2. HPMC Swellable 
polymer
30 60 90 40 80 120 50 100 150
3. Starch 
(Paste)
Binding agent 24 24 24 32 32 32 40 40 40
4. Magnesium 
Stearate
Lubricant 3 3 3 4 4 4 5 5 5
5. Talc Glidant 3 3 3 4 4 4 5 5 5
Total coat 
weight
----- 300 300 300 400 400 400 500 500 500
LBG : 
HPMC ratio
----- 8:1 7:2 6:3 8:1 7:2 6:3 8:1 7:2 6:3
Core : Coat 
ratio
----- 1:3 1:3 1:3 1:4 1:4 1:4 1:5 1:5 1:5
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subject ingested barium sulfate containing compression 
coated tablets of optimized batch (based upon in vitro drug 
release studies) orally with 250 mL of water. The tablets 
were visualized using x-ray. Abdominal radiographs were 
taken at fixed time intervals (after 2, 5, 8, 12, 16 and 20 
hours) and tablets were visualized for site and time range 
of disintegration of tablet in the colon. The volunteers were 
served with light breakfast at 2 hour post-dose. This was 
followed by a standard lunch at 4 hour post-dose. Tea was 
given at 8 hour post-dose and a standard dinner was given 
at 12 h post-dose (Demiroz et al., 2004). The experimental 
protocol and consent for in vivo studies were approved by 
Institute Review Board.
FTIR spectral studies
The KBr pellets with neat drug 5-fluorouracil, 
powdered tablet formulation of optimized batch CLH63 
(selected on the basis of in vitro drug release studies) 
before storage, after storage and placebo tablet formulation 
of optimized batch were prepared. A FTIR (Shimadzu, 
FTIR 8400S, Japan) spectrophotometer was used to 
record IR spectra of the prepared pellets in the range of 
400-4000 cm-1 with a resolution of 1 cm-1 to confirm the 
absence of chemical interaction of 5-fluorouracil with 
excipients of core as well as compression coated tablets.
Differential scanning colorimetric studies
The possibility of any interaction between 
5-fluorouracil and locust bean gum or other excipients 
used in the formulation during tablet processing was 
further assessed by carrying out the thermal analysis on 
pure drug 5-fluorouracil, powdered tablet formulation of 
optimized batch CLH63 before storage and after storage 
at 40 ± 2 oC/75 ± 5% RH for six months by constant 
rate heating (CRH) method proposed by international 
confederation for thermal analysis and calorimetry 
(ICTAC). The DSC curves of the samples were obtained 
at a standard scanning rate of 10 oC/min conducted over a 
temperature range of 0 to 350 oC.
Stability Studies
To assess the long term stability of the compression 
coated tablet formulations, the optimized batch formulation 
(CLH63) were stored at 40 ± 2 oC/75 ± 5% RH for a period 
of six months. Samples were observed for any physical 
change, compressional characteristics and drug content. At 
the end of six months storage study period, the initial (zero 
time) results were compared with post-stability testing 
period results. The powdered samples of 5-fluorouracil 
compression coated tablet formulations CLH63 were also 
subjected to DSC and FTIR studies.
RESULTS AND DISCUSSION
The outer coat of LBG and HPMC function as the 
rate controlling mechanism of 5-fluorouracil release from 
compression coated tablets, therefore the core tablets 
were prepared with fast disintegration and dissolution 
characteristics. Tested in USP disintegration tester (Elico, 
India), the core tablets were found to disintegrate within 
1 min showing required fast disintegration characteristic 
and over 95% of 5-fluorouracil dissoluted in pH 1.2 buffer 
within 30 min. The fast disintegration and dissolution 
of the core tablet prevent it from being the rate limiting 
factor for release of 5-fluorouracil from compression 
coated tablets soon after degradation of the biodegradable 
polysaccharide material locust bean gum content present 
in the coat by the caecal enzymes in rat caecal medium. 
The physical property of the 5-fluorouracil core tablet 
was given in Table III. The core tablet complied with 
pharmaceutical standards and falls within the limits of 
Indian pharmacopoeia for weight variation, hardness, 
friability and drug content uniformity.
All batches (A, B and C series) of compression 
coated tablets were produced under similar conditions 
to avoid influence of processing variables. The coated 
tablets of different formulations were subjected to various 
evaluation tests, such as hardness, friability, weight 
variation, drug content uniformity and in vitro dissolution. 
Physical evaluation results of all the formulations are 
shown in Table III. In a weight variation test, mass 
values of the coated tablets were between 1.03% and 
2.90%. The average percentage deviation of all tablet 
formulations was found to be within the limit, and hence 
all formula tions passed the test for uniformity of weight 
as per offi cial requirements. The hardness of tablets 
was between 5.92 ± 0.38 and 6.32 ± 0.13 kgcm–2. The 
percentage friability of all the formulations was between 
0.238 and 0.447%. Tablets that lose less than 1% of their 
weight are generally acceptable. In the present study, 
the percen tage friability for all the formulations was 
below 0.5%, indicating that their friability was within the 
prescribed limits. Values of the hardness test and percent 
friability indicate good handling properties of the prepared 
coated tablets. The drug content uniformity ran ged from 
98.06 ± 3.02 to 100.03 ± 1.32% which ensures uniformity 
in drug content in all the coated formulations. 
The ability of 5-fluorouracil compression coated 
tablets to remain intact in the physiological environment 
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of stomach and small intestine was assessed by conducting 
in vitro drug release studies in pH 1.2 buffer for 2 hours, 
then in phosphate buffer pH 7.4 for 3 hours and continued 
in phosphate buffer pH 6.8 up to 24 hours without and with 
rat caecal content in dissolution medium. The results of the 
in vitro drug release studies carried out on 5-fluorouracil 
core tablets compression coated with a combination of 
locust bean gum and HPMC in different ratios (8:1, 7:2 
and 6:3) and coat weights (300 mg, 400 mg and 500 mg) 
are shown in Figure 1, 2 and 3.
The percent 5-fluorouracil released from formulation 
ALH81, ALH72, ALH63, BLH81, BLH72, BLH63 was 
5.85%, 6.92%, 7.52%, 2.59%, 3.36%, 5.42%, respectively, 
in the first 5 hour of dissolution studies in simulated 
gastric (2 hours) and intestinal fluid (3 hours) as shown 
in Figure 1 and 2. From the release profile it was clear 
that all the formulations with a coat weight of 300 and 
400 mg fails to control drug release during the initial 5 h 
of dissolution studies in simulated gastric (2 hours) and 
TABLE III - Physical evaluation study for 5-fluorouracil core and compression coated tablets
Formulation
Hardness
(kg g cm-2 ± SD)
(n=5)
Friability
(%)
(n=10)
Drug Content
(% ± SD)
(n=10)
 Weight Variation
(%)
(n=20)
5-FLU core 
ALH81
ALH72
ALH63
BLH81
BLH72
BLH63
CLH81
CLH72
CLH63
CLH63*
3.10 ± 0.12
5.92 ± 0.38
5.98 ± 0.14
6.04 ± 0.15
5.96 ± 0.27
6.02 ± 0.69
6.22 ± 0.13
6.32 ± 0.13
6.12 ± 0.24
6.06 ± 0.19
5.64 ± 0.15
0.637
0.334
0.285
0.397
0.338
0.238
0.258
0.331
0.447
0.298
0.615
100.89 ± 1.58
99.72 ± 2.82
99.58 ± 1.51
100.03 ± 1.32
98.19 ± 2.72
98.69 ± 2.09
99.27 ± 2.03
98.06 ± 3.02
98.91 ± 1.83
99.23 ± 1.62
97.75 ± 0.89
2.01
1.03
1.46
2.38
2.68
1.98
1.34
2.90
1.60
2.30
1.58
* Data obtained after storage period of 6 months at 40 oC/75% RH.
FIGURE 1 - In vitro release profile of 5-fluorouracil from 
formulation coated with 300 mg without and with rat caecal 
medium (RCM).
FIGURE 2 - In vitro release profile of 5-fluorouracil from 
formulation coated with 400 mg without and with rat caecal 
medium (RCM).
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FIGURE 3 - In vitro release profile of 5-fluorouracil from 
formulation coated with 500 mg without and with rat caecal 
medium (RCM).
intestinal fluid (3 hours). This may be due to the reduced 
coat weights (300 mg and 400 mg) used around the 
5-fluorouracil core tablet, which might not be sufficient 
to form a thick viscous gel layer around the core tablet 
to prevent drug release in the first 5 h and were higher 
as the coat weight decreased around the core tablet. The 
release of drug ranging from 2.59% to 7.52% in the first 
5 hours is a serious consideration for anti cancer drug like 
5-fluorouracil which shows deleterious effects on stomach 
and small intestine.
The oral drug delivery systems targeted to colon 
should protect the drug being released in the stomach 
and small intestine. Hence, the coat weight was increased 
to 500 mg (core coat ratio 1:5) in tablets formulation 
CLH81, CLH72 and CLH63 as shown in Table II with an 
objective to prevent the initial premature drug release in 
upper gastrointestinal region. The formulation CLH81, 
CLH72 and CLH63 released no drug in the first 5 hours 
of dissolution study in simulated gastric and intestinal 
fluid as shown in Figure 3. This suggests that LBG-HPMC 
mixture with a coat weight of 500 mg can effectively 
controls the release of the drug in the first 5 hours of 
dissolution studies. This might be due to high coat weight 
used around the core tablet and forming a viscous gel layer 
which retards seeping of dissolution fluid in to the core 
formulation and controls diffusion of drug from the core 
into dissolution fluid. It is clearly evident from the in vitro 
release data that on increasing the coat weight around the 
core tablet minimized the drug release in the initial 5 hours. 
This might be due to fact that increased coat weights forms 
a thick viscous gel layer around the core tablet which 
resulted in an increased resistance of coat to dissolution 
fluid, causing decreased fluid imbibition consequently 
causing a decrease in rate of dissolution of drug in core, 
and ultimately resulted in a decline in drug release.
To assess the integrity of the polysaccharide LBG 
coat the drug release studies were carried out without 
addition of rat ceacal content to pH 6.8 phosphate buffer 
dissolution media. At the end of 24 h of dissolution study, 
the formulation ALH81, ALH72, ALH63, BLH81, BLH72, 
BLH63 CLH81, CLH72 and CLH63 were highly swollen 
and mean percent drug released was 71.76%, 75.60%, 
77.41%, 59.84%, 62.47%, 68.13%, 48.22%, 51.72%, 
53.94% respectively. It is evident from in vitro release 
data that, the drug release from all the formulations were 
found to be incomplete in the physiological environment 
of colon during the dissolution testing period of 24 hours. 
This indicates that the locust bean gum present in the coat 
is not degraded, which was expected to degrade in rat 
caecal medium, increasing the release of the remaining 
5-fluorouracil drug present in the core tablet formulation 
in to the rat caecal content medium.
The percent 5-fluorouracil released in presence of 
4% rat caecal content medium from formulation ALH81, 
ALH72, ALH63 , BLH81, BLH72, BLH63, CLH81, 
CLH72 and CLH63 was found to be 98.16%, 98.27%, 
99.51% 97.52%, 98.16%, 98.34%, 85.94%, 95.73% and 
96.18%, respectively, at the end of 24 hour as shown in 
Figure 1, 2 and 3. The release profiles revealed that drug 
release was increased rapidly and more then 95% of the 
drug was released from all the formulations except CLH81 
in rat caecal medium compared with that in with out rat 
caecal content medium. The formulation CLH81 released 
only 85.94% of the drug, this is due to high proportion of 
LBG content present in the coat shell which might have 
not disintegrated completely during the dissolution testing 
period of 24 hours in rat caecal medium. The increase in 
the release rate in rat caecal medium was most probably 
due to biodegradation of LBG present in the coat by 
colonic bacterial enzymes. It is evident from the Figure 1, 
2 and 3 that the coat weights used for coating around the 
core tablet had a marked effect on drug release rate in the 
rat caecal content medium. As the coat weight decreases, 
rate of degradation of LBG in rat caecal medium increases, 
which caused increment of drug release from formulations. 
It could be seen that release rate was higher in formulation 
of A and B series compared with that in formulation of C 
series, where proportion of LBG or coat weight was higher. 
The rate of drug release was found to increase from 8 h in 
all the formulations with a coat weight of 300 and 400 mg 
and in formulations with a higher coat weight of 500 mg 
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the release rate was found to increase from 12 hours. The 
in vitro results revealed that for protecting 5-fluorouracil 
core tablet in the physiological environment of stomach 
and small intestine, the 5-fluorouracil core tablet should 
be coated with a higher coat weight (500 mg).
In vitro release studies in the presence of rat caecal 
content indicated the suitability of the polysaccharide 
locust bean gum based compression coated tablets for 
colonic delivery of 5-fluorouracil in case of LBG and 
HPMC mixture in the ratio 6:3 with a coat weight of 
500 mg as coating materials. However, the evaluation 
of the dosage form in human renders support to in vitro 
studies. Hence, X-ray studies were carried out on healthy 
human volunteer to access the in vivo performance and 
to support in vitro drug release studies of the optimized 
batch formulation CLH63. The studies were carried out 
using barium sulphate as X-ray opaque material. As per the 
advice of a well-known radiologist of the city, the time and 
amount of radiation exposed to volunteers would be more 
if γ-scintigraphy technique is adopted. Also γ-scintigraphy 
technique utilizes the radiotracers, which may harm 
the volunteers. Further, X-ray visualization of tablet 
disintegration performance has been studied by many 
researchers (Munira, Pundarikakshudu, 2007). Hence, it 
was proposed to use roentegenography technique which 
is comparatively safer technique. The optimized batch 
compression coated tablet formulation CLH63 containing 
barium sulphate was ingested by the health volunteers and 
images were taken at different time intervals. The position 
of the test tablet formulation throughout GI system at 
different time points were shown in Figure 4.
From the abdominal radiographs taken at different 
time intervals, it is evident that tablet remained unchanged 
form in the stomach and after 2 hour it is found in the 
jejunum as shown in Figure 4 (A). After 5 hours, the 
tablet appeared to be slightly swollen but remained intact 
and reached the ileocecal region without disintegrating in 
the upper region of GI tract this is due to the resistance 
of the coat to the stomach and intestinal fluid. The X-ray 
images showed that the tablets slowly disintegrated in the 
colon (ascending colon/hepatic flexure) after reaching 
colon between 5 and 8 hours of post administration. It is 
evidenced by reduction in swollen tablet size appeared 
in X-ray images taken after 8 hours, 12 hours and 16 
hours. This can be attributed to a possible degradation 
of locust bean gum and solubilization of HPMC present 
in the coat in the physiological environment of colon. 
Complete disintegration of the tablet was seen clear after 
20 hours post administration. This was attributed by the 
disappearance of the tablet as shown in X-ray image Figure 
4 (F). These results are in agreement with the results 
of Ashford et al. (1993) who observed that the gastric 
emptying time of 0.6-2.9 hour, small intestine transit time 
of 1.8-8.5 hours and colonic arrival time of 3.2-9.8 hours 
while evaluating pectin as a compression coat for colonic 
drug delivery, using gamma scintigraphy.
The FTIR spectrum of 5-fluorouracil  (A), 
formulation CLH63 before storage (B) and formulation 
CLH63 after storage (C) and placebo formulation of 
CLH63 (D) are represented in Figure 5. In case of FTIR 
spectra of 5-fluororuacil, bands at 3053 cm-1, 3014 cm-1 
and 2825 cm-1 are attributed to both aromatic and aliphatic 
C−H stretching vibrations. A band at 1726 cm-1 represents 
the imide group stretching of heterocyclic ring. A band 
at 1661 cm-1 is due to the tertiary amide group stretching 
vibration. N−H bending vibration is observed at 1517 cm-
1. A band at 1236 cm-1 shows C−N stretching vibrations. 
FIGURE 4 - The X-ray images at different time points showing 
tablet formulation CLH63 localization in the gastrointestinal 
tract.
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The C-F stretching band was observed at 806 cm-1. When 
FTIR spectra of 5-fluorouracil were compared with 
FTIR spectra of compression coated tablet formulation 
CLH63 (before storage and after storage) there was no 
change in the position of the principal peaks/bands of 
5-fluorouracil. This further confirms the integrity of 
pure drug 5-fluorouracil and their compatibility with the 
excipients of core as well as compression coated tablets.
DSC curves of 5-fluorouracil (A), formulation 
CLH63 before storage (B) and formulation CLH63 
after storage (C) and placebo formulation of CLH63 
(D) obtained by constant rate heating (CRH) / constant 
rate thermal analysis (CRTA) method proposed by 
international confederation for thermal analysis and 
calorimetry (ICTAC) are shown in Figure 6. DSC curve 
of 5-fluorouracil showed a single sharp endothermic 
peak at 284.5 oC, which was ascribed to drug melting. 
The endothermic peak corresponding to melting point of 
5-fluorouracil in formulation CLH63 before storage did 
not show any significant shift in the endothermic peak 
285.68oC. The DSC curve of formulation CLH63 after 
storing at 40 ºC/75 % RH for 6 months, the endothermic 
FIGURE 6 - DSC curves of 5-fluorouracil (A), formulation 
CLH63 before storage (B), formulation CLH63 after storage 
(C) and placebo formulation of CLH63 (D).
FIGURE 5 - FTIR spectra of 5-fluorouracil (A), formulation 
CLH63 before storage (B), formulation CLH63 after storage 
(C) and placebo formulation of CLH63 (D).
peak was slightly shifted to 275.17 oC. The findings of 
the DSC study further confirmed absences of interaction 
between 5-fluorouracil and excipients used in the core as 
well as compression coated tablets.
It was observed that, there was no significant change 
in hardness, friability, weight variation and drug content 
uniformity of the optimized batch formulation CLH63 
after storage at 40 oC/75% RH for 6 months as shown in 
Table III. Figure 7 represents the in vitro release profile 
of 5-fluorouracil from optimized tablet batch formulation 
CLH63 after storage period of six months and there was no 
significant difference in the percent 5-fluorouracil released 
from the same formulation CLH63 before storage. This 
indicates that the formulation CLH63 could provide a 
minimum shelf life of 2 years (Mathews, 1999).
CONCLUSION
From the results of in vitro dissolution profile, we 
are able to conclude that fast disintegrating 5-fluorouracil 
core tablet compression coated with a coat formulation 
CLH63 found to be suitable for successful colonic delivery 
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of 5-fluorouracil without being released in physiological 
environment of stomach and small intestine. In vivo 
X-ray studies using healthy human volunteers were also 
performed in which coat formulation CLH63 showed 
disintegration of the tablet in the ascending colon between 
8 to 16 hours of post dose. Therefore, this study lays a 
basis for use of polysaccharide LBG along with HPMC 
for compression coating as one of the novel approaches 
for colonic delivery of 5-fluorouracil for the treatment of 
colon cancer.
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